Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

v3.5.0.2
7. Stockholders' Equity (Details Narrative) - USD ($)
3 Months Ended 7 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Jul. 19, 2016
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dividends earned $ 0 $ 268,927   $ 0 $ 1,589,321  
Stock issued for services, value       $ 9,310    
Unrecognized compensation cost amortization period       1 year 4 months 10 days    
Gain on change in fair value of warrants 2,087,041 $ 190,000   $ 6,813,701 190,000  
Proceeds from sale of stock     $ 7,300,000 7,521,036 0  
Stock Options [Member]            
Unrecognized compensation cost 400,000     $ 400,000    
Unrecognized compensation cost amortization period       1 year 7 months 2 days    
Options granted       20,798,500    
Cashless Exercise of Warrants [Member]            
Stock issued for conversion of securities, shares issued       48,783    
Previously Converted Preferred Stock [Member]            
Stock issued for conversion of securities, shares issued       50,606    
Public Offering [Member]            
Stock issued new, shares       19,115,000    
Proceeds from sale of stock       $ 7,500,000    
Public Offering [Member] | Overallotments [Member]            
Warrants Issued       303,633    
Medytox [Member] | Common stock to employees and consultants [Member]            
Share based compensation expense         2,900,000  
Medytox [Member] | Outstanding options [Member]            
Share based compensation expense         500,000  
Warrant Exercises [Member]            
Stock issued for warrants exercised       43,809    
Previously converted preferred stock [Member]            
Shares issued in adjustment of prior conversion of preferred stock, shares       50,606    
Previously issued to employee [Member]            
Stock cancelled, shares       40,964    
Epinex Diagnostics [Member]            
Stock cancelled, shares       45,000    
Consultant [Member]            
Stock issued for services, shares issued       13,300    
Stock issued for services, value       $ 9,310    
Three Officers [Member]            
Stock issued for compensation, shares       583,335    
Employee [Member]            
Share based compensation expense       $ 200,000    
Restricted stock granted       83,334    
Employees, Directors and Consultants [Member]            
Share based compensation expense       $ 700,000    
Employees, Directors and Consultants [Member] | May 2, 2016 [Member]            
Options granted       15,643,000    
Employees, Directors and Consultants [Member] | July 17, 2016 [Member]            
Options granted       5,155,500    
Medytox Series B Preferred Stock [Member]            
Dividends earned         $ 1,600,000  
Accrued dividends $ 100,000     $ 100,000   $ 2,100,000
Preferred stock converted into common, common shares issued         5,733,945  
Series C Preferred Stock [Member]            
Preferred stock converted into common, preferred shares converted       260    
Preferred stock converted into common, common shares issued       167,743    
Series C Preferred Stock [Member] | Exchange Agreement [Member]            
Preferred stock converted into common, preferred shares converted       8,740    
Warrants exchanged       6,451,613    
Series G Preferred Stock [Member]            
Preferred stock converted into common, preferred shares converted       4,182    
Preferred stock converted into common, common shares issued       9,292,905    
Series G Preferred Stock [Member] | Exchange Agreement [Member]            
Preferred stock converted into common, common shares issued       13,793    
Exhange warrants issued       10,249,517    
Warrant conversion price $ .45     $ .45    
Gain on change in fair value of warrants       $ 1,700,000